New ALS Treatment Doses Undergoing Phase 1 Trial
The Phase 1 ANQUR clinical trial for QRL-201, a potential treatment for amyotrophic lateral sclerosis (ALS), has completed its dose-escalation phase and is now testing two new doses to determine the safest and most effective levels. The trial, which involves patients with sporadic ALS and those with C9ORF72 mutations, is ongoing at 12 sites in Canada and Europe. QRL-201 aims to restore levels of the protein STMN2, crucial for nerve stability, by correcting abnormal mRNA processing. Initial results show promising therapeutic levels in cerebrospinal fluid, supporting further testing.
